HENGRUI PHARMA (600276.SH) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" for SHR-4610 injection from the National Medical Products Administration (NMPA). Clinical trials will commence shortly.
SHR-4610 injection is an innovative anti-tumor drug independently developed by the company. It has demonstrated promising anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors.
As of now, the cumulative R&D investment in the SHR-4610 injection project amounts to approximately RMB 7.36 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.